Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Franklin Resources Inc.

Franklin Resources Inc. raised its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 141.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,091 shares of the company's stock after buying an additional 90,920 shares during the quarter. Franklin Resources Inc.'s holdings in Teva Pharmaceutical Industries were worth $2,674,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of TEVA. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $50,000. Sanctuary Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock valued at $601,000 after buying an additional 664 shares during the period. TCW Group Inc. bought a new stake in Teva Pharmaceutical Industries in the third quarter worth $1,286,000. Geode Capital Management LLC boosted its stake in Teva Pharmaceutical Industries by 3.4% during the third quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company's stock worth $157,571,000 after buying an additional 291,124 shares during the period. Finally, Barclays PLC increased its position in Teva Pharmaceutical Industries by 31.7% during the third quarter. Barclays PLC now owns 427,595 shares of the company's stock valued at $7,705,000 after acquiring an additional 102,848 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares of the company's stock, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Christine Fox sold 19,388 shares of the company's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Barclays raised their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a report on Wednesday, December 18th. StockNews.com downgraded Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, October 21st. Finally, UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of "Moderate Buy" and a consensus price target of $20.88.

Teva Pharmaceutical Industries Stock Up 0.9 %

Teva Pharmaceutical Industries stock traded up $0.20 during mid-day trading on Thursday, reaching $22.62. 7,484,542 shares of the company were exchanged, compared to its average volume of 9,422,448. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The firm has a market cap of $25.63 billion, a P/E ratio of -26.61, a PEG ratio of 0.99 and a beta of 0.79. The business has a fifty day moving average of $18.06 and a 200 day moving average of $17.64. Teva Pharmaceutical Industries Limited has a 12-month low of $10.39 and a 12-month high of $22.80.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.